Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
150 hedge funds and large institutions have $1.09B invested in Acorda Therapeutics in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 22 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
1% less funds holding
Funds holding: 152 → 150 (-2)
13% less capital invested
Capital invested by funds: $1.26B → $1.09B (-$170M)
65% less call options, than puts
Call options by funds: $4.38M | Put options by funds: $12.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.5M |
| 2 |
HEC
Hudson Executive Capital
New York
|
+$10M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$9.65M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$7.08M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$21.3M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$16.2M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$14.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.2M |
ACOR Hedge Fund Activity: Q4 2017 in Review
150 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2017, worth a combined $1.09B — down 13% from $1.26B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ACOR and 20 opened new positions — a net loss of 2 holders — while 53 trimmed existing stakes and 55 added.
The largest buyer was Morgan Stanley, adding an estimated $10.5M. The largest seller was Fidelity Investments, cutting an estimated $27.5M.
- 150 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2017, down from 152 in Q3 2017.
- Funds reported $1.09B of Acorda Therapeutics stock for Q4 2017, down 13% quarter-over-quarter.
- 20 funds opened new Acorda Therapeutics positions in Q4 2017 and 22 closed out, a net change of -2 holders.
- The largest Acorda Therapeutics buyer in Q4 2017 was Morgan Stanley, an estimated $10.5M added.
- The largest Acorda Therapeutics seller in Q4 2017 was Fidelity Investments, an estimated $27.5M sold.
Based on aggregated 13F filings for Q4 2017.